Which Will Pfizer Buy? Biogen or Bristol-Myers Squibb – Barron’s – Barron’s

But Alex Arfaei, the pharma industry analyst at BMO Capital Markets, says a marriage with biotech giant Biogen (BIIB) “would make more sense.” He argues that Biogen, as a major player in the multiple sclerosis market with a promising experimental Alzheimer’s drug in its pipeline, would help Pfizer fill#8230;

Everyone has heard the talk. Pfizer (PFE) is getting ready to make a deal. the skinny on Wall Street is that the U.S. pharmaceutical giant has its eyes set on rival Bristol-Myers Squibb (BMY) and its immuno-oncology business.

Leave a Comment

Your email address will not be published. Required fields are marked *